1PASSWORD
4.6.2024 07:01:32 CEST | Business Wire | Press release
1Password, a leader in identity security, today announced significant business momentum across Europe, the Middle East, and Africa (EMEA). With a strategic focus on the region, 1Password is expanding its workforce, launching products tailored to the EMEA market, and securing over 35% of Europe’s Top 100 companies. Today, over one-third of 1Password’s B2B customers are based in EMEA.
The majority (68%) of security breaches are still caused by a human element resulting in compromised credentials, and the company recently launched 1Password Extended Access Management (XAM), an industry-first solution designed to secure every login to every app from every device, addressing the modern workforce’s need for even more seamless and secure access. Now available in the EMEA region, this solution protects users' privacy and gives businesses strong security across managed and unmanaged applications and devices, while offering visibility and insights to help them meet resilience, compliance, and audit goals. As a leading enterprise password manager, 1Password enhances identity security by providing businesses with secure access to their most sensitive information, such as login credentials and SSH keys, actionable insights to address vulnerabilities, and seamless integration with existing security infrastructure.
1Password recently hired Oliver Cheal as Vice President, EMEA. In this role, he will oversee the company’s EMEA-based teams that are focused on designing, developing, selling, and supporting 1Password’s identity and access management solutions for customers in the region. Cheal was most recently at Cisco and Duo Security and his background is in transforming cybersecurity businesses by leading organizational change and building out the go-to-market function. With more than 100 employees in EMEA, 1Password is actively investing in its EMEA workforce, with plans to open positions across sales, marketing, customer success, and partnerships in the UK, Netherlands, and Germany.
“I am thrilled to join 1Password at such a pivotal time and grow our EMEA team to better serve our customers across the region,” said Oliver Cheal, VP of EMEA. “With 1Password Extended Access Management, we're revolutionizing access management by bridging the gaps left by traditional IAM solutions. With its seamless integration and user-friendly design, we are able to empower IT and security teams with unparalleled visibility and control, ensuring their employees can safely use the tools they need, whether working remotely or in the office.”
Earlier this year, the company launched the 1Password Global Partner Program and the 1Password® Enterprise Password Manager - MSP Edition in beta to provide resellers, distributors, and Managed Service Providers (MSPs) with the tools and resources they need to help their customers become more secure. Key strategic partners in EMEA include Amazon Web Services (AWS), Arrow Electronics, Insight Enterprises, Tap.De, and SVA.
“Watching 1Password's expansion into EMEA is incredibly exciting. Their growth and vision have always perfectly aligned with ours, and we are thrilled to be part of this journey, supporting their success every step of the way. By addressing critical security gaps with their new Extended Access Management (XAM) solution, 1Password is pioneering a new category in cybersecurity that ensures comprehensive protection across the modern, hybrid work environment and we are excited to be their partner,” said Ikramul Khaled, the Group Head of Vendor Alliances at QBS Technology Group.
For more information about 1Password, visit our website here.
About 1Password
Trusted by over 150,000 businesses and millions of consumers, 1Password offers identity security and access management solutions built for the way people work and live today. 1Password is on a mission to eliminate the conflict between security and productivity while securing every sign-in for every app on every device. As the provider of the most-used enterprise password manager, 1Password continues to innovate on its strong foundation to offer security solutions relied upon by companies of all sizes, including Associated Press, Salesforce, GitLab, Under Armour, and Intercom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603036115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom